Geographic variation in statin use for complex acute myocardial infarction patients evidence of effective care?

Medical Care

Volumn 52, Issue 3 SUPPL. 2, 2014, Pages

  Brooks, John M ^a,b   Cook, Elizabeth A ^a   Chapman, Cole G ^a   Kulchaitanaroaj, Puttarin ^a   Chrischilles, Elizabeth A ^b   Welch, Stephen ^a   Robinson, Jennifer ^b  

^a Postgraduate Year One Pharmacy Residency Program   (United Kingdom)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

AMI; Effective care; Geographic variation; Preference sensitive care; Statins

Indexed keywords

AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KIDNEY DISEASES; MALE; MYOCARDIAL INFARCTION; PATIENT CARE TEAM; PRIMARY HEALTH CARE; PRIMARY PREVENTION; QUALITY ASSURANCE, HEALTH CARE; RESIDENCE CHARACTERISTICS; UNITED STATES;

EID: 84894425193     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3182a7fc3d     Document Type: Article

References (51)

1. Wallace E, Smith SM, Fahey T. Variation in medical practice: getting the balance right. Fam Pract. 2012;29:501-502.
2. National Institute for Health and Clinical Excellence (NICE). Statins for the Prevention of Cardiovascular Events. 2006 [updated 2008]. Available at: http://www.nice.org.uk/nicemedia/pdf/TA094guidance.pdf. Accessed March 1, 2013.
3. Dartmouth Atlas of Health Care. Effective Care. 2013. Available at: http://www.dartmouthatlas.org/keyissues/issue.aspx?con=2939. Accessed March 1, 2013.
4. Fisher ES, Wennberg JE. Health care quality, geographic variations, and the challenge of supply-sensitive care. Perspect Biol Med. 2003;46: 69-79. Winter 2003. (Pubitemid 36188548)
5. Wennberg JE, Fisher ES, Skinner JGeography and the debate over Medicare reform. Health Aff. 2002. Available at: http://www.healthaffairs. org/WebExclusives/Wennberg-Web-Excl-021302.htm. doi: 10.1377/hltaff. w2.115.
6. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239. (Pubitemid 38924592)
7. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372. (Pubitemid 43947981)
8. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376:1658-1669.
9. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
10. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J. 2003;326: 1423-1427. (Pubitemid 36776152)
11. Robinson J, Davidson M. Combination therapy with ezetimibe and simvastatin to acheive aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006;4:461-476. (Pubitemid 44304551)
12. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438-445. (Pubitemid 44109954)
13. Mills EJ, O'Regan C, Eyawo O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a metaanalysis of >40 000 patients. Eur Heart J. 2011;32:1409-U1138.
14. Meek CL, Reston JD, Ramsbottom T, et al. Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80mg in primary care. Int J Clin Pract. 2011;65:120-126.
15. Crouse JR III, Elam MB, Robinson JG, et al. Cholesterol management: Targeting a lower low-density lipoprotein cholesterol concentration increases Adult Treatment Panel-III goal attainment. Am J Cardiol. 2006;97:1667-1669. (Pubitemid 43737030)
16. Javed U, Deedwania PC, Bhatt DL, et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010;160:1130-1136, 1136 e1131-1133.
17. Lewis WR, Ellrodt G, Peterson E, et al. Trends in the use of evidencebased treatments for coronary artery disease among women and the elderly: findings from the Get With the Guidelines Quality-Improvement Program. Circulation. 2009;2:633-641.
18. McGinnis BD, Olson KL, Delate TM, et al. Statin adherence and mortality in patients enrolled in a secondary prevention program. Am J Manag Care. 2009;15:689-695.
19. Zuckerman IH, Yin X, Rattinger GB, et al. Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults. J Am Geriatr Soc. 2012;60:1854-1861.
20. Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm. 2008;14:271-280. (Pubitemid 351711978)
21. Donohue JM, Morden NE, Gellad WF, et al. Sources of regional variation in Medicare Part D drug spending. N Engl J Med. 2012;366: 530-538.
22. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676-683. (Pubitemid 44128440)
23. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol. 2006;98:1405-1408. (Pubitemid 44666653)
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
25. Shepherd J, Kastelein JJP, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448-1454. (Pubitemid 351471787)
26. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261. (Pubitemid 350190755)
27. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet. 2008;372:1231-1239.
28. Desai DA, Zakaria S, Ouyang P. Initiation of statin therapy: are there age limits? Curr Atheroscler Rep. 2012;14:17-25.
29. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690. (Pubitemid 37430274)
30. Waters DD. Safety of high-dose atorvastatin therapy. Am J Cardiol. 2005;96(5A):69F-75F. (Pubitemid 41207736)
31. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-414. (Pubitemid 43228152)
32. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10:373-387.
33. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29:1761-1770. (Pubitemid 47494553)
34. Golomb BA, McGraw JJ, Evans MA, et al. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30:669-675. (Pubitemid 47295826)
35. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373-418.
36. Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf. 2012;11:439-444.
37. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23:317-324.
38. Hedenmalm K, Alvan G, Ohagen P, et al. Muscle toxicity with statins. Pharmacoepidemiol Drug Saf. 2010;19:223-231.
39. Holbrook A, Wright M, Sung M, et al. Statin-associated rhabdomyolysis: is there a dose-response relationship? Can J Cardiol. 2011;27: 146-151.
40. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781-1790. (Pubitemid 350137473)
41. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97(8A):61C-68C.
42. Ickowicz E, Panel AGSE. Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American Geriatrics Society. J Am Geriatr Soc. 2012;60:1957-1968.
43. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized controlled trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008;118:1294-1303.
44. Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med. 2011;26:783-790.
45. Cook EA, Schneider KM, Chrischilles EA, et al. Accounting for immeasurable time bias when using Medicare prescription drug data. Medicare and Medicaid Research Review. 2013. (In press).
46. Fang G, Brooks JM, Chrischilles EA. A new method to measure geographic variation in prescription use and its implications for comparative effectiveness research. Med Care. 2010;40:710-717.
47. Fang G, Brooks JM, Chrischilles EA. Comparison of instrumental variable analysis using a new instrument with risk adjustment methods to reduce confounding by indication. Am J Epidemiol. 2012;175:1142-1151.
48. Brooks JM, Chrischilles EA, Landrum MB, et al. Survival implications associated with variation in mastectomy rates for early-staged breast cancer. Int J Surg Oncol. 2012;2012:127854.
49. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267. (Pubitemid 32007842)
50. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11:375-386.
51. Wennberg JE. Which rate is right? N Engl J Med. 1986;315:810-815.